Combination Treatment Options for Castration-Resistant Prostate Cancer

Autor:	Miller DR; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, USA; Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, Ingersoll MA; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, USA; Department of Pharmacology, Creighton University, Omaha, NE, USA, Teply BA; Division of Hematology/Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, USA, Lin MF; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, USA; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, USA; Section of Urology, Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska, USA; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA; College of Pharmacy, Kaohsiung Medical University, Kaohsiung City, Taiwan
Jazyk:	angličtina
Zdroj:	2021 May 27.
DOI:	10.36255/exonpublications.prostatecancer.2021
Abstrakt:	Prostate cancer is the most commonly diagnosed solid tumor and the second leading cause of cancer-related deaths in men in the United States. While localized prostate cancer has an excellent prognosis for patients, about one-third of patients are diagnosed with high-risk disease, including metastatic cancer. The 5-year survival rate of metastatic prostate cancer is only about 30%. Due to the androgen dependence of prostate cancer cells, androgen-deprivation therapy is the standard of care for metastatic prostate cancer, which includes both surgical and medical approaches. Nevertheless, androgen-deprivation therapy in general is not curative; patients can develop castration-resistant prostate cancer. Despite current chemotherapies, including the utilization of novel androgen signaling inhibitors and immunotherapy, patients still succumb to the disease. Hence, castration-resistant prostate cancer is a lethal disease. Combination treatment is a strategy for treating this lethal disease and thus will be the focus of discussion in this chapter. (Copyright: The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu